Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immuron.
RELATED STOCKHEAD STORIES
Health & Biotech
The Ethical Investor: Why Starpharma and these ASX biotechs could stop the next infectious disease outbreak
News
CLOSING BELL: ASX closed 0.11% lower, because there was no one around last night to tell us what to do
Health & Biotech
ASX biotechs are looking up, and the FDA breakthroughs are starting to flow
Health & Biotech
ASX Health Stocks: Little Green Pharma gets French deal extension; FDA approves Immuron trial
Health & Biotech
ASX Health Stocks: Noxopharm plunges 45pc after discontinuing Veyonda clinical trials
News
Top 10 at 10: Western Mines up 315% in two days as good news keeps flowing
News
Market Highlights: Tech stocks sold off, Citi and BofA join bullish gold camp, and 5 ASX small caps to watch today
Health & Biotech
Which ASX stocks are on the path from FDA to clinical trial in 2023?
News
CLOSING BELL: It’s never a good idea to let the ASX dress all in red ‘just like Santa Claus’
News
ASX Small Caps Lunch Wrap: Whose bright idea was it to have such a horribly sad day?
News
Trading Places: BGH ups Virtus stake to above 50pc as battle for fertility company escalates
Health & Biotech
Check Up: Money managers are still bullish on Healthcare; here’s what they said
Health & Biotech
Check Up: Immuron wins big in US and Europe on travellers’ diarrhoea drug
News
Closing Bell: ASX bounces back as US markets prepare for the inflation genie
Health & Biotech
ASX Health Stocks: Immuron up 29pc on $6.2m travellers’ diarrhoea clinical study for US military
Health & Biotech
As Biotron more than doubles on promising COVID results, which other ASX stocks are working on treatments?
Health & Biotech
